Citations

Clear

4 citation(s) found for "Shafqat, Areez".

Cardiovascular Risk Assessment: A Review of Current Models and Emerging Determinants, including Biomarkers, Genetics, and Artificial Intelligence
Ec, Habib, Ibrahim, R, Humayun, Zainab , Wang, W, Abdalla, Hesham, El-Shaer, Ahmed, Nambi, Vijay , Fernandes, Regis I., Wang, Winston , Baqal, Omar , Baqal, Omar J , Shafqat, Areez , Habib, Eiad, Abdalla, Hesham, El-Shaer, Ahmed, Virani, Salim S.

Mayo Clinic

Current Cardiology Reviews | July 1, 2026 | Volume: 22 | Issue: No issue available | Pages: No page available

10.2174/011573403x421246251128050146 | PMID 42381136 Get It

Abstract: Cardiovascular disease (CVD) remains the leading cause of death worldwide. While advances in treatment have improved outcomes, the greatest gains in public health will come from primary prevention. Risk stratification is the foundation of CVD prevention. Traditional tools, such as pooled cohort equations (PCEs) and SCORE2, do not capture non-traditional risk factors and individual variability, driving efforts to refine existing approaches. We critically discuss emerging risk determinants for primary CVD prevention. Coronary artery calcium scoring can reclassify CVD risk but has limitations related to cost, access, and unvalidated improvements in clinical endpoints. Biomarkers such as apolipoprotein B and lipoprotein(a) may identify residual risk beyond LDL-C, particularly in patients with lipid discordance, but remain underused due to uncertain thresholds and the lack of prospective triallevel outcome data. Trials of colchicine in primary prevention have yielded mixed results, making the role of targeting inflammation unclear in CVD prevention. Polygenic risk scores can stratify genetic risk but face challenges in sensitivity, specificity, and generalizability. Multiomics approaches, while offering the promise of deeper phenotyping, lack established clinical applications and consensus on when their use is appropriate. Artificial intelligence may allow better prediction across cohorts but requires broader validation. Clonal hematopoiesis of indeterminate potential, a marker of inflammation and age-related CVD risk, lacks evidence supporting routine screening or intervention in younger, asymptomatic individuals. The proliferation of new risk stratification tools poses a key challenge: determining when additional data meaningfully alter clinical decisions. Until robust outcome-based evidence emerges, risk enhancers should guide, but not dictate, therapy in selected patients.
Low-dose post-transplant cyclophosphamide for GvHD prophylaxis in haploidentical stem cell transplantation: A systematic review of efficacy, toxicity, and survival outcomes
Shafqat, Areez, Ahmad, Omar, Omer, Mohammed, Shafqat, Shameel, Nasiri, Abdulrahman, Kotb, Ahmed, Mushtaq, Ali, Harnegie, Mary, Al-Ahmari, Ali, Ahmed, Syed, Rasheed, Walid, Alzahrani, Hazza, Aljurf, Mahmoud, Elfakih, Riad, Saleh, Mostafa, Shafqat, Areez, Ahmad, Omar, Omer, Mohammed, Shafqat, Shameel, Nasiri, Abdulrahman, Kotb, Ahmed, Mushtaq, Ali, Harnegie, Mary, Al-Ahmari, Ali, Ahmed, Syed, Rasheed, Walid, Alzahrani, Hazza, Aljurf, Mahmoud, Elfakih, Riad, Saleh, Mostafa

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7775-7775

10.1182/blood-2025-7775 Get It

Abstract Background: Haploidentical allogeneic stem cell transplantation (haplo-SCT) has been a transformative option for patients lacking matched donors. Post-transplant cyclophosphamide (PTCy) at 100 mg/kg total dose (50 mg/kg on Day +3 and +4) is a standard for graft-versus-host diseases (GvHD) prophylaxis. Efforts to decrease toxicity while maintaining efficacy have informed pursuits of dose de-escalation. However, data regarding the efficacy and safety of reduced-dose PTCy (<100 mg/kg) remain scattered and variably reported. Methods: We performed a systematic review registered on PROSPERO (CRD420250650291) and conducted per PRISMA guidelines. Six databases (Medline, Embase, Web of Science, Scopus, Cinahl, Cochrane) were searched initially up to May 2024. An updated search was conducted to include studies till June 2025. Eligible studies included prospective or retrospective cohorts or randomized trials evaluating low-dose PTCy in haplo-SCT recipients reporting on acute/chronic GvHD, overall survival (OS), relapse-free survival (RFS), immune reconstitution, or complications such as hemorrhagic cystitis or infections. Non-comparative studies, reviews, and abstracts were excluded. Data was extracted independently by two reviewers, and risk-of-bias (ROB) was assessed using ROBINS-I and Cochrane RoB-2 tools. Results: Thirty-three studies, including 31 observational studies and 2 randomized controlled trials (RCTs), encompassing over 2500 patients, met our eligibility criteria. Most studies originated from Asia, with smaller contributions from Europe, the United States, India and Latin America. Low-dose PTCy regimens ranged from 14.5 to 80 mg/kg, commonly administered as 50 mg/kg ×1 on day +3 or 40 mg/kg ×2 on days +3 and +4. Comparators included standard-dose PTCy (100 mg/kg), ATG-based prophylaxis, or other regimens. Median follow-up ranged from 4 months to over 5 years. Acute GvHD (grades II–IV) rates in low-dose PTCy arms ranged from 9% to 34%. Most observational data showed comparable or reduced incidence of aGvHD compared to controls. Chronic GvHD outcomes varied from 8-46% and showed no clear benefit of dose reduction in most studies.Two-year OS ranged widely from 47% to 100%, with some observational studies favoring low-dose PTCy but others showing no survival advantage. RFS was similarly variable. Hemorrhagic cystitis occurred in 3–33% of patients, with no clear dose-dependent pattern. Infections were inconsistently reported, but, when data were available, viral infections, including BK virus, CMV, and EBV reactivation, were common, with no consistent dose-dependent trend. Median time to immune reconstitution was slightly shorter in some cohorts, but clinical relevance remains uncertain. Two studies reported significantly reduced incidence of cardiac complications with lower PTCy exposure. One randomized controlled trial comparing 80 mg/kg PTCy + ATG with the Beijing Protocol reported significantly reduced aGvHD (11.5% vs. 39.3%, p=0.001) and better OS (75.4% vs. 54.1%, p = 0.021) and RFS ((72.7% vs. 55.0%, p = 0.044)) in the experimental arm. In contrast, the only other randomized study used ultra-low-dose PTCy (14.5 mg/kg ×2) vs. ATG and found no significant difference in acute GvHD (18.2% vs. 18.2%, p=0.996) or survival and was stopped early because of futility. Both RCTs showed comparable rates of cGvHD, toxicity, and immune reconstitution.Importantly, 87% of observational studies had a serious or critical ROB. Both RCTs had some concerns of bias due to inadequate allocation concealment and open-label design but were otherwise at low ROB. Conclusions: Low-dose PTCy for GvHD prophylaxis in haplo-SCT carries comparable or lower rates of acute GvHD, similar chronic GvHD incidence, and non-inferior survival outcomes in many studies. Marked heterogeneity in regimens, patient populations, high ROB, and selective reporting preclude definitive conclusions. Randomized trials must focus on identifying subgroups benefiting from de-escalated PTCy. Until then, low-dose PTCy remains a promising but investigational alternative in haploidentical transplantation.
Ablation Strategies for Persistent Atrial Fibrillation: Beyond the Pulmonary Veins
Baqal, Omar , Shafqat, Areez , Kulthamrongsri, Narathorn , Sanghavi, Neysa , Iyengar, Shruti Krishna , Vemulapalli, Hema Srikanth , Masry, Hicham El , Iyengar, Shruti K, Vemulapalli, Hema S , El Masry, Hicham , Baqal, Omar J , Kulthamrongsri, Narathorn

Mayo Clinic

Journal of Clinical Medicine | August 26, 2024 | Volume: 13 | Issue: 17 | Pages: 5031

10.3390/jcm13175031 | PMID 39274244 Get It

Despite advances in ablative therapies, outcomes remain less favorable for persistent atrial fibrillation often due to presence of non-pulmonary vein triggers and abnormal atrial substrates. This review highlights advances in ablation technologies and notable scientific literature on clinical outcomes associated with pursuing adjunctive ablation targets and substrate modification during persistent atrial fibrillation ablation, while also highlighting notable future directions.
Machine learning applications and challenges in graft-versus-host disease: a scoping review
Mushtaq, Ali , Hashmi, Shahrukh K. , Muhsen, Ibrahim N. , Muhsen, Ibrahim N , Mushtaq, Ali , Shafqat, Areez , Salah, Haneen

Mayo Clinic

Current Opinion in Oncology | October 11, 2023 | Volume: 35 | Issue: 6 | Pages: 594-600

10.1097/cco.0000000000000996 | PMID 37820094 Get It

Purpose of review This review delves into the potential of artificial intelligence (AI), particularly machine learning (ML), in enhancing graft-versus-host disease (GVHD) risk assessment, diagnosis, and personalized treatment. Recent findings Recent studies have demonstrated the superiority of ML algorithms over traditional multivariate statistical models in donor selection for allogeneic hematopoietic stem cell transplantation. ML has recently enabled dynamic risk assessment by modeling time-series data, an upgrade from the static, “snapshot” assessment of patients that conventional statistical models and older ML algorithms offer. Regarding diagnosis, a deep learning model, a subset of ML, can accurately identify skin segments affected with chronic GVHD with satisfactory results. ML methods such as Q-learning and deep reinforcement learning have been utilized to develop adaptive treatment strategies (ATS) for the personalized prevention and treatment of acute and chronic GVHD. Summary To capitalize on these promising advancements, there is a need for large-scale, multicenter collaborations to develop generalizable ML models. Furthermore, addressing pertinent issues such as the implementation of stringent ethical guidelines is crucial before the widespread introduction of AI into GVHD care.